Health AI Central
Share:
Peer-Reviewed Publication
Br J Haematol2026August 18, 2026Journal Article

Danburstotug, an anti-PD-L1 antibody, in relapsed/refractory extra-nodal natural killer/T-cell lymphoma: The phase 2 DISTINKT study.

Won Seog Kim1, Seok Jin Kim1, Jae-Cheol Jo2, Sang Eun Yoon1, Youngil Koh3, Deok-Hwan Yang4, Dok Hyun Yoon5, Junhun Cho6, Sung Young Lee7, Suyeon Kim7, Seongyeon Kang7, Woochan Hwang8, Hyukjung Kim8, Hwi-Yeol Yun9, Jihyun Jeon9, Chul Ahn10, Heung Tae Kim7
1Division of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
2Department of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Republic of Korea.
3Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea.
4Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Hwasun, Jeollanam-do, Republic of Korea.
5Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
6Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
7ImmuneOncia Therapeutics Inc., Seoul, Republic of Korea.
8Lunit Inc., Seoul, Republic of Korea.
9College of Pharmacy, Chungnam National University, Daejeon, Republic of Korea.
10Department of Health Data Science and Biostatistics, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
PubMed DOI

Abstract

Relapsed/refractory extra-nodal natural killer/T-cell lymphoma (R/R ENKTL) has limited treatment options. Danburstotug, an antibody targeting programmed death-ligand 1 (PD-L1), was evaluated in adults with R/R ENKTL in a phase 2, open-label study (NCT04414163). Danburstotug 20 mg/kg was administered intravenously every 2 weeks up to 52 cycles, disease progression or unacceptable toxicity. In the f…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.